We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+2.71%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.21B
AUM Growth
-$76.7M
Cap. Flow
-$36.6M
Cap. Flow %
-3.01%
Top 10 Hldgs %
64.48%
Holding
49
New
3
Increased
11
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$47.8M
2
NTLA icon
Intellia Therapeutics
NTLA
+$38.4M
3
WGS icon
GeneDx Holdings
WGS
+$34.6M
4
GPCR icon
Structure Therapeutics
GPCR
+$15.9M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$8.56M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$36.4M
2
ILMN icon
Illumina
ILMN
+$23.1M
3
MXCT icon
MaxCyte
MXCT
+$22.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$20.1M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLFS icon
1
BioLife Solutions
BLFS
$1.56B
$165M 13.57%
7,571,535
+5,243
+0.1% +$118K
SRPT icon
2
Sarepta Therapeutics
SRPT
$1.63B
$160M 13.17%
1,160,000
-155,000
-12% -$20.1M
RLAY icon
3
Relay Therapeutics
RLAY
$4.04B
$93.9M 7.73%
5,698,574
+2,667,926
+88% +$47.8M
EQRX
4
DELISTED
EQRx, Inc. Common Stock
EQRX
$76.7M 6.32%
39,527,669
– –
ILMN icon
5
Illumina
ILMN
$30.2B
$64M 5.27%
282,700
-113,080
-29% -$23.1M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$29.1B
$54.1M 4.46%
270,000
-95,000
-26% -$20M
NTLA icon
7
Intellia Therapeutics
NTLA
$1.5B
$47.5M 3.91%
1,275,000
+980,000
+332% +$38.4M
PLRX icon
8
Pliant Therapeutics
PLRX
$64.4M
$44.6M 3.67%
1,675,000
– –
RVMD icon
9
Revolution Medicines
RVMD
$38.8B
$39.2M 3.23%
1,810,000
-715,000
-28% -$17.6M
EXAS
10
DELISTED
Exact Sciences
EXAS
$38.3M 3.16%
565,000
– –
WGS icon
11
GeneDx Holdings
WGS
$1.98B
$37.3M 3.07%
3,095,509
+2,597,403
+521% +$34.6M
SLGC
12
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$32.1M 2.65%
12,604,275
– –
VERV
13
DELISTED
Verve Therapeutics
VERV
$30.6M 2.52%
2,120,571
-170,000
-7% -$3.33M
BPMC
14
DELISTED
Blueprint Medicines
BPMC
$30.1M 2.48%
670,000
-807,800
-55% -$36.4M
DNLI icon
15
Denali Therapeutics
DNLI
$3.67B
$30M 2.47%
1,300,000
– –
MXCT icon
16
MaxCyte
MXCT
$116M
$24.4M 2.01%
4,925,000
-4,580,000
-48% -$22.6M
TSVT
17
DELISTED
2seventy bio
TSVT
$20.6M 1.7%
2,023,913
+173,913
+9% +$1.99M
ABCL icon
18
AbCellera Biologics
ABCL
$1.78B
$19M 1.57%
2,520,000
+250,000
+11% +$2.27M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$19M 1.56%
510,000
+35,000
+7% +$1.57M
FDMT icon
20
4D Molecular Therapeutics
FDMT
$524M
$18.4M 1.52%
1,070,000
+440,000
+70% +$8.56M
BEAM icon
21
Beam Therapeutics
BEAM
$2.66B
$17.5M 1.44%
570,000
+200,000
+54% +$7.89M
TNYA icon
22
Tenaya Therapeutics
TNYA
$161M
$17.3M 1.43%
6,078,860
– –
GPCR icon
23
Structure Therapeutics
GPCR
$3.39B
$16.1M 1.33%
+677,017
New +$15.9M
RXDX
24
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$16.1M 1.33%
150,000
– –
RNAM
25
DELISTED
Avidity Biosciences
RNAM
$13M 1.07%
850,000
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q1 2023 Portfolio in Review

As of Q1 2023, Casdin Capital held 49 positions worth $1.21B, down 5.9% from $1.29B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Casdin Capital withdrew a net $36.6M in Q1 2023, closing 8 positions and reducing 10 holdings. Its most notable exit was Moderna, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

Against the trend, Casdin Capital opened a new position in Structure Therapeutics worth $16.1M.

  • Casdin Capital's largest Q1 2023 buy was Structure Therapeutics: 677,017 shares worth $16.1M.
  • Casdin Capital added most to Relay Therapeutics in Q1 2023, an estimated $47.8M increase.
  • Casdin Capital's biggest Q1 2023 reduction was Blueprint Medicines, cutting an estimated $36.4M.
  • Casdin Capital fully exited Moderna in Q1 2023, selling an estimated $10.8M.
  • Casdin Capital's ten largest holdings make up 64% of its $1.21B portfolio in Q1 2023.
  • Casdin Capital opened 3 new positions and closed 8 in Q1 2023.
  • Casdin Capital's portfolio value fell 5.9% quarter-over-quarter to $1.21B.

Based on Casdin Capital's 13F filing for Q1 2023, filed 15 May 2023.